G1 Therapeutics Inc Stock News

RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik,.

RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced...

Wall Street analysts expect G1 Therapeutics Inc (NASDAQ:GTHX) to post earnings of ($0.97) per share for the current quarter, according to Zacks. Zero analysts have made estimates for G1 Therapeutics�

G1 Therapeutics (NASDAQ:GTHX) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Monday, ValuEngine reports. Several other equities analysts have al

BidaskClub upgraded shares of G1 Therapeutics (NASDAQ:GTHX) from a strong sell rating to a sell rating in a report issued on Thursday morning, BidAskClub reports. GTHX has been the topic of several ot

RESEARCH TRIANGLE PARK, N.C., Feb. 06, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.

We can readily understand why investors are attracted to unprofitable companies. For example, although...

G1 Therapeutics (NASDAQ:GTHX) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday, ValuEng

Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Garry Nicholson to

Alpine Global Management LLC bought a new stake in G1 Therapeutics Inc (NASDAQ:GTHX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund

Quantum Leap Healthcare Collaborative™ and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a collaboration to evaluate trilaciclib, an investigational therapy designed to improve outcomes for p

Quantum Leap Healthcare Collaborative™ (QLHC) and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a collaboration to evaluate trilaciclib, an investigational therapy designed to improve outcome

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported additional data from the Phase 1b/2a clinical trial investigating its oral CDK4/6 inhibitor lerociclib in combin

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2019 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.